<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39438966</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">0778-7367</ISSN><JournalIssue CitedMedium="Print"><Volume>82</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>Archives of public health = Archives belges de sante publique</Title><ISOAbbreviation>Arch Public Health</ISOAbbreviation></Journal><ArticleTitle>Aberrations in medically certified sick leave and primary healthcare consultations in Norway in 2023 compared to pre-COVID-19-pandemic trends.</ArticleTitle><Pagination><StartPage>187</StartPage><MedlinePgn>187</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">187</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13690-024-01411-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Since 2022, Norway has employed a vaccine-only COVID-19 strategy. Primary healthcare in Norway uses International Classification of Primary Care version 2 (ICPC-2) codes. This study aims to systematically compare medically certified sick leave and primary healthcare consultations in 2023 with the pre-pandemic 2010-2019 trends, and subsequently estimate the magnitude of these changes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">For the respective outcomes of (A) working person-years lost to medically certified sick leave (WYLSL) and (B) number of primary healthcare consultations, 556 and 85 ICPC-2 code combinations were extracted from the Norwegian Labour and Welfare Administration's sick leave registry and the Norwegian Syndromic Surveillance System. For each ICPC-2 code combination, a Bayesian linear regression was performed using data between 2010 and 2019 to estimate an expected baseline for 2023, which was then used to calculate the deviation from the pre-pandemic trend. A false discovery rate of 5% was used to account for multiple testing.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All years from 2020 to 2023 had excess WYLSL, corresponding to 14,491 (90% PI: 8,935 to 20,016) in 2020, 12,911 (90% PI: 5,916 to 19,996) in 2021, 21,263 (90% PI: 12,627 to 29,864) in 2022, and 24,466 (90% PI: 14,023 to 34,705) in 2023. This corresponded to an economic loss of approximately 1.5&#xa0;billion USD in 2023. Excess WYLSL due to A* (General and unspecified) increased from 2020 to 2023, with an estimated excess of 4,136 WYLSL in 2023 (69% higher than expected). More than half of this increase was explained by A04 (Weakness/tiredness general), whose excess WYLSL in 2023 were estimated at 2,640 (80% higher than expected). The excess in A04 (Weakness/tiredness general) corresponded to an economic loss of 161&#xa0;million USD and accounted for 11% of the total excess WYLSL in 2023. The excess WYLSL in R* (Respiratory) in 2023 was 3,408, which correspond to an economic loss of 207&#xa0;million USD and accounted for 14% of the total excess in 2023.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Significant excesses in working person-years lost to medically certified sick leave and primary healthcare consultations in 2023. A sizable proportion of the excesses were due to diseases/symptoms associated with acute and post-acute sequelae of COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>White</LastName><ForeName>Richard Aubrey</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Norwegian Institute of Public Health, Oslo, Norway. RichardAubrey.White@fhi.no.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Chi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valcarcel Salamanca</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Norwegian Institute of Public Health, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angelsen</LastName><ForeName>Aslaug</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zakiudin</LastName><ForeName>Dinastry Pramadita</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andries</LastName><ForeName>Aristomo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kabashi</LastName><ForeName>Saranda</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Norwegian Labour and Welfare Administration, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moberg</LastName><ForeName>Lene Lehmann</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Norwegian Labour and Welfare Administration, Oslo, Norway.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Arch Public Health</MedlineTA><NlmUniqueID>9208826</NlmUniqueID><ISSNLinking>0778-7367</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="nor"><AbstractText Label="BAKGRUNN" NlmCategory="BACKGROUND">Siden 2022 har Norge hatt en &#xab;kun vaksine&#xbb;-basert strategi for covid-19. Prim&#xe6;rhelsetjenesten i Norge bruker ICPC-2-koder. Denne studien har som m&#xe5;l &#xe5; systematisk sammenligne legemeldt sykefrav&#xe6;r og konsultasjoner i prim&#xe6;rhelsetjenesten i 2023 med trendene fra f&#xf8;r pandemien i perioden 2010&#x2013;2019, og deretter estimere st&#xf8;rrelsen p&#xe5; disse endringene.</AbstractText><AbstractText Label="METODER" NlmCategory="UNASSIGNED">For utfallene (A) tapte arbeids&#xe5;r (tapte arbeidsdager delt p&#xe5; 250) p&#xe5; grunn av legemeldte sykefrav&#xe6;r og (B) antall konsultasjoner i prim&#xe6;rhelsetjenesten, ble 556 og 85 ICPC-2-kodekombinasjoner hentet fra NAVs sykefrav&#xe6;rsregister og Det norske syndromiske overv&#xe5;kingssystemet. For hver ICPC-2-kodekombinasjon ble det utf&#xf8;rt en Bayesiansk line&#xe6;r regresjon ved bruk av data fra 2010&#x2013;2019 for &#xe5; estimere en forventet baseline for 2023, som deretter ble brukt til &#xe5; beregne avviket fra trendene f&#xf8;r pandemien. En falsk oppdagelsesrate p&#xe5; 5% ble brukt.</AbstractText><AbstractText Label="RESULTATER" NlmCategory="UNASSIGNED">&#xa0;Alle &#xe5;r fra 2020 til 2023 viste et overskudd av tapte arbeids&#xe5;r, tilsvarende 14 491 (90% PI: 8935 til 20 016) i 2020, 12 911 (90% PI: 5916 til 19 996) i 2021, 21 263 (90% PI: 12 627 til 29 864) i 2022 og 24 466 (90% PI: 14 023 til 34 705) i 2023. Dette tilsvarte et &#xf8;konomisk tap p&#xe5; omtrent 16,7 milliarder NOK i 2023. Overskuddet i tapte arbeids&#xe5;r pga. A* (Allment og uspesifisert) &#xf8;kte fra 2020 til 2023, med et beregnet overskudd p&#xe5; 4136 tapte arbeids&#xe5;r i 2023 (69% h&#xf8;yere enn forventet). Mer enn halvparten av denne &#xf8;kningen ble forklart av A04 (Slapphet/tretthet), hvor overskudd i tapte arbeids&#xe5;r i 2023 ble beregnet til 2640 (80% h&#xf8;yere enn forventet). Overskuddet i A04 (Slapphet/tretthet) tilsvarte et &#xf8;konomisk tap p&#xe5; 1,8 milliarder NOK. Overskuddet i tapte arbeids&#xe5;r pga. R* (Luftveier) i 2023 var 3408, noe som tilsvarte et &#xf8;konomisk tap p&#xe5; 2,3 milliarder NOK og utgjorde 14% av det totale overskuddet i 2023.</AbstractText><AbstractText Label="FORTOLKNING" NlmCategory="UNASSIGNED">Betydelig overskudd i b&#xe5;de tapte arbeids&#xe5;r p&#xe5; grunn av legemeldt sykefrav&#xe6;r og konsultasjoner i prim&#xe6;rhelsetjenesten i 2023. En betydelig del av overskuddene skyldes sykdommer/symptomer knyttet til akutt covid-19 og senf&#xf8;lger av covid-19.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae of COVID-19</Keyword><Keyword MajorTopicYN="N">Primary healthcare</Keyword><Keyword MajorTopicYN="N">Sick leave</Keyword></KeywordList><CoiStatement>RAW and BVS are employed by the Norwegian Institute of Public Health, which is responsible for providing guidance and recommendations regarding COVID-19 in Norway. The other authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39438966</ArticleId><ArticleId IdType="pmc">PMC11495095</ArticleId><ArticleId IdType="doi">10.1186/s13690-024-01411-4</ArticleId><ArticleId IdType="pii">10.1186/s13690-024-01411-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>The Economist. 2024. Available from: https://www.economist.com/graphic-detail/coronavirus-excess-deaths-estimates.</Citation></Reference><Reference><Citation>Beyrer C. A pandemic anniversary: 40 years of HIV/AIDS. Lancet. 2021;397(10290):2142&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">34087110</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat Med. 2023;29:2347&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10504070</ArticleId><ArticleId IdType="pubmed">37605079</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuang S, et al. Experiences of Canadians with long-term symptoms following COVID-19. Statistics Canada. 2023. https://www150.statcan.gc.ca/n1/pub/75-006-x/2023001/article/00015-eng.htm.</Citation></Reference><Reference><Citation>Kostka K, Roel E, Trinh NTH, Mercad&#xe9;-Besora N, Delmestri A, Mateu L, et al. The burden of post-acute COVID-19 symptoms in a multinational network cohort analysis. Nat Commun. 2023;14:7449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10656441</ArticleId><ArticleId IdType="pubmed">37978296</ArticleId></ArticleIdList></Reference><Reference><Citation>Agergaard J, Gunst JD, Schi&#xf8;ttz-Christensen B, &#xd8;stergaard L, Wejse C. Long-term prognosis at 1.5 years after infection with wild-type strain of SARS-CoV-2 and Alpha, Delta, as well as Omicron variants. Int J Infect Dis. 2023;137:126&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">37907167</ArticleId></ArticleIdList></Reference><Reference><Citation>Knudsen AKS, Madsen C, Forthun I, Tvedten HM, Dahl J, Lyngstad TM, et al. D&#xf8;delighet i Norge under koronapandemien 2020&#x2013;2022. Oslo: Norwegian Institute of Public Health; 2023.</Citation></Reference><Reference><Citation>Ministry of Health and Care Services. Regjeringens strategi og beredskapsplan for h&#xe5;ndteringen av covid-19-pandemien. Oslo:&#xa0;Ministry of Health and Care Services; 2023.</Citation></Reference><Reference><Citation>Norwegian Institute of Public Health. Epidemier av luftveisinfeksjoner i Norge vinteren 2023-24: risio, scenarioer og h&#xe5;ndtering. Oslo: Norwegian Institute of Public Health; 2023.</Citation></Reference><Reference><Citation>Todal PA. Med smitte skal landet vernast.&#xa0;Oslo: Dag og Tid; 2024. p. 10.</Citation></Reference><Reference><Citation>Knudsen AKS, Forthun I, Madsen C, Dahl J, Lyngstad TM, Tvedten HM, et al. D&#xf8;delighet i Norge under koronapandemien 2020&#x2013;2023. Oslo: Norwegian Institute of Public Health; 2024.</Citation></Reference><Reference><Citation>Himmels J, Lund H, Brurberg K. Post COVID-19 condition after Omicron: rapid review. Oslo: Norwegian Institute of Public Health; 2023.</Citation></Reference><Reference><Citation>Moberg L. Utviklingen i legemeldt sykefrav&#xe6;r &#xc5;ret 2023. Oslo: Norwegian Labour and Welfare Administration; 2024.</Citation></Reference><Reference><Citation>Magnusson K, Turkiewicz A, Flottorp S, Englund M. Prevalence of long COVID complaints in persons with and without COVID-19. Sci Rep. 2023;13:6074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10100609</ArticleId><ArticleId IdType="pubmed">37055494</ArticleId></ArticleIdList></Reference><Reference><Citation>Okkes I, Jamoulle M, Lamberts H, Bentzen N. ICPC-2-E: the electronic version of ICPC-2. Differences from the printed version and the consequences. Fam Pract. 2000;17(2):101&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10758069</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson D, Koren C, Hopp P, Jonsson M, R&#xf8; G, White R, et al. A one health real-time surveillance system for nowcasting Campylobacter gastrointestinal illness outbreaks, Norway, week 30 2010 to week 11 2022. Euro Surveillan. 2022;27:2101121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9615412</ArticleId><ArticleId IdType="pubmed">36305333</ArticleId></ArticleIdList></Reference><Reference><Citation>Statistics Norway. Salary and workforce costs. 2024. Available from: https://www.ssb.no/arbeid-og-lonn/lonn-og-arbeidskraftkostnader/statistikk/lonn. Cited 2023 03 1.</Citation></Reference><Reference><Citation>Statistics Norway. Labor survey. 2023. Available from: https://www.ssb.no/statbank/table/05111/. Cited 2024 03 01.</Citation></Reference><Reference><Citation>Stan Development Team.&#xa0;{RStan}: the {R} interface to {Stan}.&#xa0;R package version 2.32.3.&#xa0;2024.&#xa0;https://mc-stan.org/.</Citation></Reference><Reference><Citation>R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2023.</Citation></Reference><Reference><Citation>Norwegian Institute of Public Health. Resultater fra FHIs pilot for avl&#xf8;psoverv&#xe5;king av SARS-CoV-2. 2023. Available from: https://www.fhi.no/sm/overvaking/overvaking-smittsomme-sykdommer-i-avlopsvann/resultater-fra-avlopsovervakingen/. Cited 2024 3 1.</Citation></Reference><Reference><Citation>Mohammed I, Nauman A, Paul P, Ganesan S, Chen K, Jalil SMS, et al. The efficiacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. Hum Vaccines Immunotherapeutics. 2022;18(1):2027160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8862168</ArticleId><ArticleId IdType="pubmed">35113777</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen R, Levy C, Rybak A, Angoulvant F, Ouldali N, Grimprel E. Immune debt: recrudescence of disease and confirmation of a contested concept. Infect Dis Now. 2023;53(2):104638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9756601</ArticleId><ArticleId IdType="pubmed">36535583</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin R. From immunity debt to immunity theft-how COVID-19 might be tied to recent respiratory disease surges. JAMA. 2024;331(5):378&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">38198193</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Davis PB, Berger N, Kaelber DC, Volkow N, Xu R. Association of COVID-19 with respiratory syncytial virus (RSV) infections in children aged 0&#x2013;5 years in the USA in 2022: a multicentre retrospective cohort study. Fam Med Community Health. 2023;11(4):e002456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10582888</ArticleId><ArticleId IdType="pubmed">37832975</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumwichar P, Chongsuvivatwong V. COVID-19 pneumonia and the subsequent risk of getting active pulmonary tuberculosis: a population-based dynamic cohort study using national insurance claims databases. eClinicalMedicine. 2023;56:101825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9854255</ArticleId><ArticleId IdType="pubmed">36694864</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study. Lancet Infect Dis. 2024;24(3):239&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">38104583</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucharski AJ, Lessler J, Read JM, Zhu H, Jiang CQ, Guan Y, et al. Estimating the life course of influenza A(H3N2) antibody responses from cross-sectional data. PLoS Biol. 2015;13(3):e1002082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4348415</ArticleId><ArticleId IdType="pubmed">25734701</ArticleId></ArticleIdList></Reference><Reference><Citation>Moberg L, Kabashi S. Sykefrav&#xe6;r etter covid-19. Arbeid Og Velferd. 2023;2:25&#x2013;40.</Citation></Reference><Reference><Citation>Brage S, Nossen J, Thune O. Flere blir sykmeldt for symptomer og plager. Arbeid Og Velferd. 2013;2:88&#x2013;98.</Citation></Reference><Reference><Citation>Jason L, Dorri J. ME/CFS and post-exertional malaise among patients with long COVID. Neurol Int. 2022;15(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9844405</ArticleId><ArticleId IdType="pubmed">36648965</ArticleId></ArticleIdList></Reference><Reference><Citation>Kielland A, Lui J, Jason L. Do diagnostic criteria for ME matter to patient experience with services and interventions? Key results from an online RDS survey targeting fatigue patients in Norway. J Health Psychol. 2023;28(13):1189&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10619179</ArticleId><ArticleId IdType="pubmed">37114822</ArticleId></ArticleIdList></Reference><Reference><Citation>Norwegian Directorate of Health. Utbrenthet (P29 Psykiske symptomer/plager). 2024. Available from: https://www.helsedirektoratet.no/veiledere/sykmelderveileder/diagnosespesifikke-anbefalinger-for-sykmelding/psykisk-p/utbrenthet-p29-psykiske-symptomerplager. Cited 2024 June 1.</Citation></Reference><Reference><Citation>Mizrahi B, Sudry T, Flaks-Manov N, Tehezkelli Y, Kalkstein N, Akiva P et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. 2023;380:e072529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Sillett R, Zhu L, Mendel J, Camplisson I. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry. 2022;9(10):815&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9385200</ArticleId><ArticleId IdType="pubmed">35987197</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H, McCorkell L, Vogel J, Topol E. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellingjord-Dale M, Brunvoll S, S&#xf8;raas A. Prospective Memory Assessment before and after Covid-19. New England J Med. 2024;390(9):863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11156183</ArticleId><ArticleId IdType="pubmed">38416436</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampshire A, Azor A, Atchison C, Trender W, Hellyer P, Giunchiglia V, et al. Cognition and memory after Covid-19 in a large community sample. N Engl J Med. 2024;390(9):806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7615803</ArticleId><ArticleId IdType="pubmed">38416429</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D. Paid sick leave and risks of all-cause and cause-specific mortality among adult workers in the USA. Int J Environ Res Public Health. 2017;14(10):1247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5664748</ArticleId><ArticleId IdType="pubmed">29048337</ArticleId></ArticleIdList></Reference><Reference><Citation>Str&#xf8;m M, Sveen K, Raknes G, Slung&#xe5;rd G, Fager&#xe5;s S. D&#xf8;ds&#xe5;rsaker i Norge 2022. Oslo: Norwegian Institute of Public Health; 2023. Report No.: 978-82-8406-385-0.</Citation></Reference><Reference><Citation>Str&#xf8;m MS, Sveen KA, Raknes G, Slung&#xe5;rd GF, Reistad SR. D&#xf8;ds&#xe5;rsaker i Norge 2023. Oslo: Norwegian Institute of Public Health; 2024. Report No.: 978-82-8406-457-4.</Citation></Reference><Reference><Citation>Norwegian Labour and Welfare Administration. Utbetalinger til personer i Norge. 2023. https://www.nav.no/no/nav-og-samfunn/statistikk/flere-statistikkomrader/utbetalinger-til-personer-i-norge-per-fylke-og-kommune. Cited 2024 May 5.</Citation></Reference><Reference><Citation>The Government of Norway. Timeline: news from Norwegian Ministries about the Coronavirus disease Covid-19. 2023. Available from: https://www.regjeringen.no/en/topics/health-and-care/public-health/timeline-for-news-from-norwegian-ministries-about-the-coronavirus-disease-covid-19/id2692402/. Cited 2024 March 1.</Citation></Reference><Reference><Citation>Woldegiorgis M, Cadby G, Ngeh S, Korda RJ, Armstrong P, Maticevic J, et al. Long COVID in a highly vaccinated by largely unexposed Australian population following the 2022 SARS-CoV-2 Omicron wave: a cross-sectional survey. Med J Austral. 2024;220(6):323&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">38508863</ArticleId></ArticleIdList></Reference><Reference><Citation>Roessler M, Tesch F, Batram M, Jacob J, Loser F, Weidinger O, et al. Post-COVID-19-associated morbidity in children, adolescents, and adults: a matched cohort study including more than 157,000 individuals with COVID-19 in Germany. PLoS Med. 2022;19:1&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9648706</ArticleId><ArticleId IdType="pubmed">36355754</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker L. Record absenteeism: Belgians increasingly reporting sick at work.&#xa0;Brussels: The Brussels Times; 2024.&#xa0;https://www.brusselstimes.com/863249/record-absenteeism-belgians-increasingly-reporting-sick-at-work.</Citation></Reference><Reference><Citation>Agence France Presse. Germany's economy ails, as sick leave hurts output.&#xa0;New York City: Barron's; 2024.&#xa0;https://www.barrons.com/news/germany-s-economy-ails-as-sick-leave-hurts-output-087dcc0e.</Citation></Reference><Reference><Citation>Hussain A. Civil service sickness absence, 2023: report. London: UK Cabinet Office; 2024.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>